AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Meprylcaine hydrochloride is primarily used to induce local anesthesia by blocking nerve impulses in a specific area of the body. It works by inhibiting the influx of sodium ions through voltage-gated sodium channels in nerve cell membranes, thereby preventing the generation and conduction of nerve impulses responsible for transmitting pain signals.
Topical Anesthesia: Meprylcaine hydrochloride is often formulated as a topical cream, gel, or solution for application to the skin or mucous membranes. It is commonly used to provide local anesthesia for minor surgical procedures, skin biopsies, wound debridement, and dermatological treatments such as laser therapy or tattoo removal.
Fast Onset of Action: Meprylcaine hydrochloride typically exhibits a rapid onset of action, with local anesthesia occurring within minutes after application to the target area. This quick onset makes it suitable for use in outpatient settings and emergency departments where immediate pain relief is required.
Short Duration of Action: The duration of anesthesia provided by meprylcaine hydrochloride is relatively short-lived compared to other local anesthetics. It typically lasts for 30 minutes to a few hours, depending on factors such as the dose, concentration, and site of administration. Repeat applications may be necessary for prolonged procedures or ongoing pain relief.
Low Systemic Toxicity: Meprylcaine hydrochloride is generally well-tolerated when used as directed for local anesthesia. Its systemic absorption is minimal, reducing the risk of systemic toxicity and adverse effects commonly associated with systemic administration of local anesthetics, such as lidocaine or bupivacaine.
Adverse Reactions: While meprylcaine hydrochloride is considered safe for topical use, potential adverse reactions may include local irritation, allergic reactions, burning or stinging sensation at the application site, and transient numbness or tingling. Serious systemic side effects such as central nervous system toxicity or cardiovascular effects are rare but may occur with excessive dosing or inadvertent intravascular injection.
Contraindications: Meprylcaine hydrochloride should not be used in patients with known hypersensitivity or allergic reactions to the drug or its components. Caution is advised when administering meprylcaine to individuals with preexisting cardiac arrhythmias, severe liver or kidney dysfunction, or compromised immune function.
Pediatric and Geriatric Use: Special precautions should be taken when using meprylcaine hydrochloride in pediatric or geriatric populations. Lower doses may be required in these age groups to minimize the risk of adverse effects. Close monitoring of patients is essential to ensure safety and efficacy.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 0.3 | 0.3 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
Allergies | 0 | 0.8 | 0 |
Allergy to milk products | 0.1 | 0.1 | 0 |
Alzheimer's disease | 0.5 | 0.7 | -0.4 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0 | 0 |
Ankylosing spondylitis | 0.9 | 0.5 | 0.8 |
Anorexia Nervosa | 0.1 | 0.2 | -1 |
Antiphospholipid syndrome (APS) | 0.3 | 0.1 | 2 |
Asthma | 0.1 | -0.1 | |
Atherosclerosis | 0.1 | 0.3 | -2 |
Atrial fibrillation | 0.5 | 1.1 | -1.2 |
Autism | 1.8 | 1.5 | 0.2 |
Barrett esophagus cancer | 0.1 | 0 | 0 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.3 | 0.4 | -0.33 |
Brain Trauma | 0.1 | -0.1 | |
Carcinoma | 0.3 | 0.1 | 2 |
Celiac Disease | 0.1 | 0.3 | -2 |
Cerebral Palsy | 0 | 0.1 | 0 |
Chronic Fatigue Syndrome | 0.6 | 1.2 | -1 |
Chronic Kidney Disease | 0.5 | 0.4 | 0.25 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.4 | -3 |
Chronic Urticaria (Hives) | 0.1 | 0.8 | -7 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.1 | 1 |
Colorectal Cancer | 0.6 | 0 | 0 |
Constipation | 0.1 | 0.1 | 0 |
Coronary artery disease | 0.4 | 0.3 | 0.33 |
COVID-19 | 0.6 | 1.6 | -1.67 |
Crohn's Disease | 1.4 | 0.7 | 1 |
cystic fibrosis | 0.1 | 0.1 | 0 |
deep vein thrombosis | 0.1 | 0.1 | 0 |
Depression | 0.8 | 1.5 | -0.88 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.4 | 0 | 0 |
Endometriosis | 0.5 | 0.5 | |
Eosinophilic Esophagitis | 0.1 | 0.1 | |
Epilepsy | 0.2 | 0.3 | -0.5 |
Fibromyalgia | 0.4 | 1.5 | -2.75 |
Functional constipation / chronic idiopathic constipation | 0.4 | 1.2 | -2 |
gallstone disease (gsd) | 0.1 | 0.2 | -1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0 | 0 |
Generalized anxiety disorder | 0.5 | 0.4 | 0.25 |
Glioblastoma | 0 | 0 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 0.1 | 0.1 | 0 |
Halitosis | 0.2 | 0 | 0 |
Hashimoto's thyroiditis | 0.1 | 0.2 | -1 |
Hidradenitis Suppurativa | 0.2 | 0.2 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | 0 |
hyperglycemia | 0 | 0.1 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.2 | 0.6 | -2 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.1 | 0.1 | |
IgA nephropathy (IgAN) | 1.3 | -1.3 | |
Inflammatory Bowel Disease | 0.5 | 1.5 | -2 |
Insomnia | 0.1 | 0.1 | 0 |
Intelligence | 0.3 | 0.8 | -1.67 |
Intracranial aneurysms | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 0.3 | 0.2 | 0.5 |
Liver Cirrhosis | 0.8 | 0.6 | 0.33 |
Long COVID | 1.4 | 0.9 | 0.56 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0 | 0 | |
ME/CFS with IBS | 0 | 0.7 | 0 |
ME/CFS without IBS | 0.5 | 0.1 | 4 |
Metabolic Syndrome | 1.2 | 0.8 | 0.5 |
Mood Disorders | 1.2 | 1.5 | -0.25 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 0.3 | 1.1 | -2.67 |
Neuropathy (all types) | 0 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 0.4 | 1 |
Obesity | 1 | 0.7 | 0.43 |
obsessive-compulsive disorder | 0.2 | 1.5 | -6.5 |
Osteoarthritis | 0.4 | 0.4 | |
Osteoporosis | 0.1 | 0.1 | 0 |
pancreatic cancer | 0 | 0 | |
Parkinson's Disease | 0.6 | 0.7 | -0.17 |
Polycystic ovary syndrome | 0.2 | 0.1 | 1 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
Psoriasis | 0.1 | 1.3 | -12 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.6 | 2.33 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 0.6 | 0.4 | 0.5 |
scoliosis | 0.3 | 0.1 | 2 |
Sjögren syndrome | 0.9 | 0.2 | 3.5 |
Sleep Apnea | 0.4 | 0.5 | -0.25 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
Stress / posttraumatic stress disorder | 0.4 | 0.5 | -0.25 |
Systemic Lupus Erythematosus | 1.1 | 0.1 | 10 |
Tic Disorder | 0.8 | -0.8 | |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 0.5 | 0.1 | 4 |
Type 2 Diabetes | 1.2 | 0.8 | 0.5 |
Ulcerative colitis | 0.2 | 1.4 | -6 |
Unhealthy Ageing | 1.2 | 0.4 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.